A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects

NCT03304964 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: FP-025 (MMP-12 inhibitor)
DRUG: FP-025 (MMP-12 inhibitor)
DRUG: FP-025 (MMP-12 inhibitor)
DRUG: FP-025 (MMP-12 inhibitor)
DRUG: FP-025 (MMP-12 inhibitor)

Sponsor

Foresee Pharmaceuticals Co., Ltd.